This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Discover methods to keep discipline in updated budgets, such as setting recurring reviews and reinforcing goals after changes.
20,110 articlesA GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
As Nvidia prepares to report earnings in May, investors weigh AI momentum against valuation. This practical guide exp...
Applied Optoelectronics leads a broad optics rally, jumping 24% as AI-driven data-center capex fuels demand for high-...
As 2026 accelerates, a wave of deals reshapes the cybersecurity landscape. Analysts spotlight targets likely to be ac...
Investors are weighing the latest earnings from First Majestic Silver. This article breaks down what the numbers mean...
A chorus of caution from michael burry, paul tudor and a Nobel-winning peer signals a potential reversal in a tech-le...
Three under-$10 energy names are drawing attention as one yields 8.8%, another is up 83% in a year, and market chatte...
The phrase oklo stock sinking today captures the mood around Oklo’s latest earnings and market reaction. This guide b...
A Taboola director disclosed a sizable open-market sale of 61,000 shares. This article explains what insider trades c...
A startup unveils a proprietary lithium extraction process that dramatically shortens timelines and boosts recovery, ...
Cisco beat estimates on a robust AI infrastructure push, delivering record revenue and higher AI targets as the stock...
Palantir's 2025 results set a high-growth trajectory, but investors want to know how the stock could perform by 2030....